Celltrion Wins FDA Approval for First Subcutaneous Version of IBD Drug Infliximab
BioSpace
OCTOBER 23, 2023
The regulator has approved the first-ever subcutaneous version of infliximab, an IgG1 monoclonal antibody, commonly sold by Johnson & Johnson under the brand name Remicade.
Let's personalize your content